GERMANTOWN, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it will host an in-person and virtual analyst event in conjunction with the American Diabetes Association 85th Scientific Sessions (ADA 2025), on Saturday, June 21, 2025 at 8:00am CT at the Marriot Marquis Chicago. To register, click here.

The event will feature company management who will discuss the next-generation Eversense® 365 Continuous Glucose Monitoring (CGM) system, approved by the U.S. Food and Drug Administration (FDA) for people with diabetes aged 18 years and older.

Along with comments from management, the event will feature Brian Hansen (Ascencia Diabetes Care), who will speak to the commercial launch of Eversense 365, and Gary Graf, MSN, APRN-C (Cotton-O’Neil Diabetes and Endocrinology Center), who will speak to experience with the Eversense system and the insertion procedure. Company management will also discuss the recently announced partnership with Sequel to integrate with the twiist automated insulin delivery pump and plans to advance its pipeline of implantable CGM technology.

A live question and answer session will follow the formal presentations.

About Senseonics

Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

INVESTOR CONTACT:
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com